Lupin LMS Joins PolyPeptide to Expand Global Peptide API Supply

Lupin Ltd announced today that its subsidiary, Lupin Manufacturing Solutions has entered into a longterm agreement with PolyPeptide Group AG.

The joint venture will strengthen the global peptide-based active pharmaceutical ingredients supply chain, since the demand of it is increasing across the world.

PolyPeptide Group AG produces and designs APIs that are oligonucleotide and peptide. The two firms will cooperate with the agreement in adding additional sources, maintaining constant supplies, and satisfying the growing global demand of peptide APIs, particularly those required to treat metabolic ailments.

Also Read: Advancing Interventional Radiology in India Through Collaboration

The joint buying, supply planning, same quality standards and reliable global delivery are the areas of interest in the partnership. The alliance intends on leveraging the strengths of each other to create a more resilient, more effective, and prepared supply chain by expanding on the increasing market on peptide. The Lupin Manufacturing Solutions- PolyPeptide alliance assists in new peptide therapy development and commercialization in key regions as well.

The CEO of LMS, Abdelaziz Toumi, added that with the increased use of peptide therapies, access to special materials that can be trusted upon is the factor that will make the large scale production successful.

According to the chief commercial officer of PolyPeptide Group, Stéphane Varray, by collaborating with Lupin Manufacturing Solutions, the company can become more flexible and provide more supply to satisfy the growing customer demand, particularly with large-scale manufacturing of metabolic therapies.

Lupin Limited is a multinational pharmaceutical company with well established presence in the United States, India, Japan and Europe; it is a company headquartered in Mumbai. It conducts research, manufactures drugs and operates worldwide supply chain. It sells a broad variety of branded and generic drugs, complex drugs, APIs, biosimilars and specialty products.